10-QPeriod: Q1 FY2010

STRYKER CORP Quarterly Report for Q1 Ended Mar 31, 2010

Filed April 29, 2010For Securities:SYK

Summary

Stryker Corporation reported strong financial performance for the first quarter of 2010, with net sales increasing 12% year-over-year to $1.8 billion. This growth was driven by robust sales in both its Orthopaedic Implants and MedSurg Equipment segments, with international sales showing a notable 12% increase, or 2% on a constant currency basis. Net earnings rose 14% to $321.7 million, translating to diluted earnings per share of $0.80, up from $0.71 in the prior year quarter. The company's liquidity position strengthened significantly, with cash and cash equivalents reaching $1.2 billion and marketable securities at $2.7 billion. This was bolstered by a substantial debt issuance of $1 billion in January 2010, which provided ample resources for working capital, potential acquisitions, and stock repurchases. Despite increased interest expenses from the new debt, Stryker's operational performance and financial health appear solid.

Financial Highlights

52 data points
Beta

Revenue

$1.80B

67.6% Gross Margin

Net Income

$322.00M

17.9% Net Margin

EPS (Diluted)

$0.80

Total Assets

$10.10B

Cash & Equivalents

$1.20B

Free Cash Flow

$243.70M

Financial Statements
Beta
Revenue$1.80B
Cost of Revenue$581.40M
Gross Profit$1.22B
R&D Expenses$90.00M
SG&A Expenses$667.80M
Operating Expenses$771.30M
Operating Income$446.40M
Net Income$322.00M
EPS (Basic)$0.81
EPS (Diluted)$0.80
Shares Outstanding (Basic)397.20M
Shares Outstanding (Diluted)400.10M

Key Highlights

  • 1Net sales grew 12% to $1.8 billion, with both domestic and international segments showing strong performance.
  • 2Orthopaedic Implants and MedSurg Equipment segments both contributed to revenue growth, with Orthopaedic Implants sales up 11% and MedSurg Equipment sales up 15%.
  • 3Net earnings increased 14% to $321.7 million, and diluted EPS grew to $0.80 from $0.71 in the prior year.
  • 4The company successfully raised $1 billion in senior unsecured notes in January 2010, significantly boosting its cash position.
  • 5Cash and cash equivalents stood at $1.2 billion, and marketable securities at $2.7 billion as of March 31, 2010.
  • 6Research, development, and engineering expenses increased 12%, reflecting an ongoing commitment to new product development.
  • 7Selling, general, and administrative expenses as a percentage of sales decreased, indicating improved operational efficiency.

Frequently Asked Questions

Stryker's sales growth in Q1 2010 was driven by increased unit volume and a favorable product mix across both its Orthopaedic Implants and MedSurg Equipment segments. Acquisitions and favorable foreign currency exchange rates also contributed to the overall 12% increase in net sales.

The issuance of $1 billion in senior unsecured notes in January 2010 significantly strengthened Stryker's liquidity. It provided approximately $996.1 million in net proceeds, which substantially increased cash and cash equivalents and marketable securities, providing flexibility for working capital, acquisitions, and stock repurchases, despite also increasing interest expenses.

Yes, Stryker is involved in several legal proceedings, including a shareholder derivative action related to product recalls and regulatory matters, a class action lawsuit concerning historical stock performance, and ongoing investigations related to Stryker Biotech LLC and foreign sales practices. While the company is cooperating and defending itself, the outcomes are uncertain and could potentially impact future financial results.

Stryker increased its R&D spending by 12% in Q1 2010, representing 5.0% of sales. This elevated spending is a strategic focus on developing new products for anticipated launches throughout the remainder of 2010 and beyond, indicating a commitment to future innovation and market position.